← Back to headlines
Piper Sandler Lowers Akebia Therapeutics Price Target to $4 Following Year-End Reports
Piper Sandler has reduced its price target for Akebia Therapeutics (AKBA) to $4, updating its estimates after the company's year-end reports.
20 Feb, 00:28 — 20 Feb, 00:28
Sources
Showing 1 of 1 sources
Related Stories
US Army Secretary Dan Driscoll Resigns After Friction With Hegseth
24m ago
Death Toll From Devastating Nepal Floods Nears 1,000 as International Aid Arrives
24m ago
Police Fatally Shoot Woman Who Killed One Person in Times Square Stabbing
25m ago
Putin and Xi Meet at Regional Security Summit in Kyrgyzstan
38m ago